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Alveolar soft part sarcoma (ASPS) is a very rare soft tissue sarcoma which arises primarily in children and young adults. Despite its
uniquehistologyandwell-characterizedgenetictranslocation,manyquestionsremainregardingthepathogenesisandtreatmentof
this tumor type. Though collective clinical experience with this tumor type spans more than 60 years, there has been little progress
made in treating this uncommon but frequently fatal disease. This paper focuses on the available data regarding its molecular
pathogenesis and insights into targeted therapeutics as well as the results of clinical trials performed to date to hopefully improve
the outcome of patients with this rare malignancy.
1.Introduction
Alveolar soft part sarcoma (ASPS) is a very rare sarcoma
which arises primarily in children and young adults. Despite
more than 60 years of experience with ASPS, several funda-
mental questions regarding this tumor type remain unans-
wered.ThetissueoforiginforASPSremainsunclear;therisk
factors which lead to tumorigenesis and clinical progression
are unknown, and the optimal approach to therapy is unde-
ﬁned. Though signiﬁcant progress has been made in the mo-
lecularcharacterizationofthistumorinthepast10yearsand
a number of exciting clinical trials are underway, this tumor
has eluded elementary characterization for many decades.
2. ClinicalFeaturesof
Alveolar Soft Part Sarcomas
Alveolar soft part sarcoma (ASPS) accounts for approxi-
mately 0.5–1% of all soft tissue sarcomas [1]. It is diagnosed
most commonly in those between 15 and 35 years of age; in
some large case series, the incidence is slightly increased in
young females by a ratio of 3:2 compared to age-matched
males [2]. Disease usually presents as a painless, soft, slow-
growing lesion that rarely causes functional impairment. In
children, ASPS most frequently occurs in the head and neck
region, especially the tongue or orbit; in older adults, it arises
from muscles of the lower or upper extremities [3–5].
Typically, this tumor grows indolently for years. Metasta-
s i si sd e t e c t e di n∼20% of patients at diagnosis and develops
in ∼80% of patients during the course of treatment [2].
Risk factors for developing this tumor remain undeﬁned,
but the risk for metastatic disease includes older age and
larger tumor size (>5cm) at diagnosis [2, 6]. ASPS, as with
most other sarcomas, most often metastasizes to the lungs,
but central nervous system involvement is also frequently
described; indeed, ASPS has been reported to metastasize to
the brain more frequently than any other form of high-grade
sarcoma [1, 7–9]. Though there have been no cases reported
of brain metastasis in the absence of lung metastasis, liver
metastasis and intraosseous extension of the tumor without
widespreaddiseasehavebeendescribed.Theprimarytumors
are often large, with a mean size of 6.5cm in one study, and
typically high vascular, such that they sometimes present as
a pulsatile mass [2]. On magnetic resonance imaging, they2 Sarcoma
may appear similar to arteriovenous malformations [10]. Ir-
regular intravascular extension is present at the tumor mar-
ginsinalmostallcases.The5-yearoverallsurvivalratesrange
from 45 to 88%, with a 20-year survival of approximately
15%; the median survival time is 6 years. Survival is dictated
largely by disease stage and the size of the primary tumor [1–
3, 6].
3.Histologic Featuresof
Alveolar Soft Part Sarcomas
Christopherson et al. were the ﬁrst to designate these tumors
as “alveolar soft part sarcomas” in 1952, given their unique
histologic appearance and uncertain tissue origin [11]. To
date, the deﬁnitive origin of this tumor remains unknown.
There is some immunohistochemical evidence suggesting
that ASPS may arise from striated muscle or pericytes, this
remains controversial [12–15]. Primary ASPS tumor sites
have also been reported in tissues where skeletal muscle is
absent, such as in the stomach, breast tissue, and the female
genital tract [16–18].
ASPS tumors are histologically distinctive. Interestingly,
this tumor type was originally named for its striking archi-
tectural similarity to respiratory alveoli; classically, poorly
diﬀerentiated tumor cells are arranged in nests separated by
thinlayersofconnectivetissuecontainingsinusoidalvascular
channels, which in turn are lined by thin endothelium [3].
A histologic variant of ASPS has been described in young
patients with lingual ASPS, which lacks the typical cellular
discohesion and thus has a solid “nonalveolar” growth pat-
tern[19].SmetanaandScottin1951weretheﬁrsttodescribe
the hallmark intracytoplasmic crystals of ASPS [20]. These
crystals are rod shaped, coarse, and basophilic bodies of
unknown signiﬁcance, though they have been shown to con-
tain monocarboxylate transporter 1 and CD147 [21]. These
cells demonstrate PAS-positive granules in almost all tumors
and often stain positively for desmin [4]. Electron micro-
scopy demonstrates rhomboid, rod shaped crystals consist-
ing of rigid ﬁbrils. In spite of these features, ASPS still may
present a diagnostic challenge, as it may resemble metastatic
renal cell carcinoma, paragangliomas, granular cell tumors,
or melanomas [3]. Preoperative imaging, usually with mag-
netic resonance imaging, is the standard of care. Core needle
biopsy or ﬁne needle aspiration should be considered before
deﬁnitive surgery. Because of the presence of intracellular
crystals, ﬁne-needle cytology can often oﬀer suﬃcient mate-
rial for diagnosis, but as with any diagnosis of solid tumor,
excisional biopsy may be required to diagnose this rare tu-
mor.
We now turn our attention to the available data con-
cerning the pathogenesis of this unique tumor, as well as the
therapeutic strategies now available.
4.MolecularPathogenesis of
Alveolar Soft Part Sarcoma
ASPS is characterized by an unbalanced translocation
between the X chromosome and chromosome 17, ﬁrst
described in a seminal paper by Ladanyi et al. in 2001
[22]. The der(17)t(X;17)(p11;25) translocation is found in
all ASPS tumors studied; in the majority of ASPS tumors,
this translocation is found in an unbalanced form, resulting
in loss of heterozygosity at 11q25 [23]. Interestingly, this
translocation is also found in a distinctive subset of renal
cell carcinomas which frequently have papillary architecture,
usually in the balanced form [24].
Elegant studies deﬁned the precise base pair position
at which this translocation occurs; the resultant fusion
protein involves the Alveolar Soft Part Sarcoma Critical
Region-1 gene (ASPSCR-1) located on chromosome 17q25
and the Transcription Factor for Immunoglobulin Heavy-
Chain Enhancer 3 (TFE3) gene, located on chromosome
Xp11.22 [22]. Structurally, the N-terminus of the ASPSCR-
1 gene is fused in-frame with the TFE3 (Transcription Factor
E 3 )g e n ea te x o n3( T y p eI )o re x o n4( T y p e2 ) ,r e s u l t i n gi n
one of two novel, functional ASPSCR1-TFE3 fusion proteins
which are capable of inducing aberrant transcription of
TFE3-regulated genes (Figure 1). At the molecular level, the
ﬁrst 234 aminoterminal aminoacids from ASPSCR-1 are
fused to the TFE3 gene at aminoacid positions 280 or 315.
There are no data as to whether these two diﬀerent fusion
products result in clinically diﬀerent diseases in terms of
presentation, metastasis, or prognosis.
The TFE3 gene is a member of the microphthalmia tran-
scription factor/transcription factor E (MITF-TFE) family
of basic helix-loop-helix leucine zipper (bHLH-Zip) tran-
scription factors along with MITF, TFEB, and TFEC [25].
TheTFE3geneexpressestheTEF3(TranscriptionEnhancing
Factor 3) protein. The MITF-TFE family of transcription
factors functions as homo- or heterodimers. They are ubiq-
uitously expressed, and each of the possible binding pairs
have been demonstrated in vitro; it has been suggested the
speciﬁc gene program activated by the TEF3 protein depends
mainly on its binding partners, which is dynamic and tissue
speciﬁc [26]. The TEF3 protein, encoded by the TFE3 gene,
also interacts with transcriptional regulators such as E2F3,
SMAD3,andLEF-1,andplaysavarietyofrolesincellgrowth
and proliferation [27].
A number of clues suggest the potential of the TFE3 gene
as a protooncogene. Early evidence demonstrated that the
TEF3 protein activates transcription via binding of its E3
motif to the EBox DNA consensus sequence (CANNTG) in
the immunoglobulin heavy-chain enhancer [28]. TEF3 reg-
ulates a number of metabolic genes which possess the EBox
in their promoters, such as the S-phase regulator cyclin E,
in an E2F3-dependent manner [27]. Interestingly, TEF3 may
confer resistance to cell cycle arrest signals and can override
arrest when ectopically expressed. For example, the presence
of TEF3 can override Rb-induced cell cycle arrest, and can
block the antimitogenic eﬀects of TGF-β in mammalian
cells [27]. TEF3 has an activating domain at both the N-
and C-termini; in vitro deletion of the N-terminal domain
results in a dominant negative form of the factor that
interferes with the function of the full-length protein [29].
This activation domain is lost in the Type 1 ASPSCR1-TFE3
gene translocation and not the Type 2 variant, though there
are no clear phenotypic diﬀerences in the tumors that ariseSarcoma 3
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Figure 1: The t(X;17)(p11;25) translocation. (a) The ASPSCR-1 gene is located at chromosome 17q25 and the TFE3 gene at Xp11. The
breakpoint found in the ASPSCR-1 gene is marked at “1”, and the two deﬁned breakpoints in the TFE3 gene are marked “2” and “3”. (b)
Following translocation, two variants of the ASPSCR-1-TFE3 fusion gene can be created. The Type 1 translocation retains the N-terminal
activation domain of the TFE3 gene.
from each of these translocations. Interestingly, 15% of cases
of renal cell carcinomas in which TFE3 gene fusions are
detected is associated with prior exposure to chemotherapy
[30]. A strong association between prior chemotherapy and
the subsequent development of ASPS has not been demon-
strated.
The ASPSCR-1 gene has been alternatively termed in
the literature TUG (Tether-containing UBX domain for
GLUT4), ASPL (alveolar soft part sarcoma locus), UBXN9,
UBXD9,a n dFLJ45380. This protein is expressed ubiqui-
tously, though it has highest expression in the adult heart
and skeletal muscle [22]. For a number of years following the
discovery of the ASPSCR1-TFE3 translocation, the function
of the ASPSCR-1 gene product was largely unknown; there
are now data that show that it functions as a tether which
interacts with the glucose transporter type 4 (GLUT4)
and cellular/organellar membranes [31]. The ASPSCR-1
protein appears to sequester the GLUT4 in intracellular
vesicles in muscle and adipocytes in the absence of insulin
and facilitates redistribution of this channel to the plasma
membrane following insulin stimulation. In the context of
a novel fusion protein, it is unclear how the anchoring
functionality of ASPSCR-1 may inﬂuence the function of
TEF3.
One may speculate that the novel N-terminus of the
ASPSCR1-TFE3 fusion protein may interfere with or obviate
the normal activation or dimerization functions of TEF3 to
the extent that normal transcription is deranged. TEF3 may
bind an alternative transcription factor, leading to aberrant
transcriptional programs or simply homodimerize in the
absence of an activating signal and remain constitutively
active. The speciﬁc role of an N-terminal segment of the
TUG protein is unclear, though hypotheses could be made
that the presence of this peptide alters dimerization or
activation of the TEF3 peptide component. It is important
to note, however, that the TFE3 gene is associated with
other tumors and a number of oncogenic translocations.
The t(X;17)(p11;25) translocation is additionally detected
in some cases of perivascular epithelioid cell neoplasms
(PEComas), and as mentioned above, and also is found in
papillary renal cell adenocarcinomas, more frequently in the
pediatric population [32]. Within this subset of renal cell
adenocarcinomas, four other TFE3 gene translocations have
been described, as shown Table 1 [22, 33–39]. Additionally,
novel chromosomal translocations have been identiﬁed
which await deﬁnition of the involved gene loci. Thus, ﬁve
discretetranslocationsassociatedwithoncogenesishavebeen
identiﬁed to date, and these translocants are thought to serve
diverse functions. This suggests that perhaps the loss of the
native N-terminus of the TFE3 gene is more important in
tumorigenesis than the particular composition of the ectopic
genetic material added to it.
In the last few years, large strides have been made in
ascertaining how the unique ASPSCR-1-TEF3 fusion protein
leads to tumorigenesis. Tsuda et al. (2007) identiﬁed that the
ASPL-TFE3 fusion protein induces strong overexpression of
the MET receptor tyrosine kinase gene in ASPS cells [40].
This group showed that in the presence of its ligand, hepato-
cyte growth factor (HGF), the MET receptor tyrosine kinase
underwent strong autophosphorylation, activating robust4 Sarcoma
Table 1: Translocations involving the TFE3 gene.
Fusion protein Genetic translocation Function of gene N-terminal to TFE3 Reference
TFE-ASPSCR-1 t(X;17)(p11;25) Tether-containing UBX domain for GLUT4 (ASPSCR-1) Ladanyi et al. [22, 24]
TFE-PRCC t(X;1)(p11.2;q21.2) Papillary renal cell carcinoma translocation-associated (PRCC) gene Weterman et al. [33]
and Sidhar et al. [34]
TFE-PSF t(X;1)(p11.2;p34) PTB-associated splicing factor (PSF)C l a r k e t a l . [ 35]
TFE-NonO inv(X)(p11.2;q12) Non-POU-domain-containing, octamer-binding (NonO)g e n e C l a r ke ta l .[ 35]
TFE-CLTC t(X;17)(p11.2;q23) Clathrin heavy-chain (CLTC)g e n e A r g a n ie ta l .[ 36]
Unknown t(X;10)(p11.2;q23) Unknown Dijkhuizen et al. [37]
Unknown t(X;3)(p11;q23) Unknown Argani et al. [38]
Unknown t(X;19)(p11.2;q13.1) Unknown Armah et al. [39]
downstreamsignalingoftheMAPkinaseandPI3K/Aktpath-
ways (Figure 2). Inhibiting expression of MET by RNA inter-
ference or a speciﬁc inhibitor abolished the HGF-dependent
MET activation, leading to decreased cell growth. These
data provide a mechanism, whereby the presence of the
ASPSCR1-TFE3 fusion protein could potentially induce cell
mitosis. Interestingly, the PSF-TFE3 and NonO-TFE3 fusion
proteins also activated this promoter, again implicating
TEF3 as the primary determinant of this phenomenon. As
mentioned, TEF3 may have broad roles in regulating mitosis
and the release of cell cycle blockade; additional parallel
signaling circuits may be similarly activated. Nonetheless,
the induction of the MET receptor tyrosine kinase pathway
by the ASPSCR-1-TFE3 fusion protein represents a major
advance in our understanding of this tumor.
5. Contemporary Therapeutic Approaches
The majority of clinical data concerning the outcomes for
those diagnosed with ASPS comes from large case series
spanning many decades, given the rarity of this tumor.
Lieberman et al. [2] provide the largest descriptive study
of patients with ASPS to date; data from 102 patients with
ASPS were collected from the years 1923 to 1986, and their
outcomes are studied. Aggregate 5-year survival was 62%
at 5 years and 18% at 20 years (median 7 years). Of 69
patients without metastasis at diagnosis, 60% remained free
of metastasis after 5 years and 15% after 20 years (median 6
years). Those who developed metastases following diagnosis
had a median survival of 2 years after discovery. The most
common sites for metastasis noted were lung, bone, and
brain, though it was noted that brain metastasis was never
detected in the absence of lung metastasis. Of those with
metastasis at diagnosis, the median survival was 3 years.
This case series provided the ﬁrst evidence that surgical
interventionappearstobetheonlyclinicallyeﬀectivetherapy
for the treatment of ASPS. Indeed, adjuvant therapies
including chemotherapy or radiation therapy yielded no
signiﬁcant diﬀerence in overall patient survival regardless of
stage, nor in the context of the presence, absence, or later
development of metastasis. In this study, of 91 patients with
localized disease who underwent primary surgical excision,
18 patients were also treated with radiotherapy, 2 with
chemotherapy, and 2 patients with both modalities. The rate
of local recurrence was not signiﬁcantly diﬀerent compared
tothosetreatedwithnoadjuvanttherapy.Similarly,adjuvant
therapy yielded no signiﬁcant diﬀerence in the number
of patients who went on to develop metastases. Finally,
no treatment modality, including chemotherapy, radiation
therapy, or surgical resection appeared to provide a survival
beneﬁt compared to those who were not treated after the
development of metastasis.
A number of similar conclusions were drawn from a
more recent study. Portera et al. [1]r e p o r td a t af r o m
74 patients collected over almost 40 years; in this study,
65% presented with American Joint Committee on Cancer
(AJCC) stage IV (metastatic) disease and the rest with AJCC
Stage II or III disease. In this series, those with nonmetastatic
disease were treated with surgery alone (9 patients) or
surgery plus external beam radiotherapy (10 patients). Three
patients were also given neoadjuvant doxorubicin prior to
surgical resection. For those with localized ASPS, the 5-year
local recurrence free, distant recurrence free, disease free,
and overall survival rates were 88%, 84%, 71%, and 87%,
respectively. Over a decade, 2 of 22 patients with localized
disease developed local recurrence, and 3 developed lung
metastasis, reﬂecting percentages similar to those reported
by Lieberman et al. From these data, radiation therapy
again did not appear to greatly inﬂuence survival or the
development of metastases, though low patient numbers
preclude deﬁnitive conclusions.
Of 48 patients presenting with Stage IV disease in this
study, 73% had metastasis to one organ, which was the lung
in ∼90% of cases. In those with more than one site of metas-
tasis,thelungwasalwaysinvolved,andbrainmetastaseswere
foundin9of29patients.Twenty-sixpatientsof33withStage
IVdiseaseweregivensystemicchemotherapywhichincluded
vincristine and/or cyclophosphamide (prior to 1970) or
doxorubicin-based therapy. The majority of patients treated
with chemotherapy (58%) developed disease progression.
This population median survival was 40 months, with a 5-
year survival rate of 20%. These data again mirror previously
described data.
Importantly, this case series showed that with more
“modern” chemotherapy regimens utilizing vincristine, cy-
clophosphamide, or doxorubicin, clinical response was dis-
appointing. Among the 26 patients with Stage IV disease
who received chemotherapy and the 3 patients with localizedSarcoma 5
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Figure 2: Signaling schematic for ASPS tumors and novel therapeutic targets. (a) Overexpression of the MET tyrosine receptor kinase is
induced by the ASPSCR1-TFE3 fusion protein. This leads to intracellular activation of the promitotic growth kinases Akt and MEK1/2; these
in turn lead to unchecked cellular proliferation. (b) Targets for novel therapeutics include the VEGF tyrosine kinase receptor and its ligand
(Recentin and Avastin, resp.), as well as tumor cell receptor tyrosine kinases (Sutent, Nexavar, and ARQ 197). Perifosine is a unique inhibitor
of the Akt kinase.
disease who received neoadjuvant doxorubicin-based sys-
temic therapy prior to resection, only a single patient stage
IV responded, though there was a complete response. Chem-
otherapy yielded no minor or incomplete responses. Thus,
this study provided little evidence that contemporary sys-
temic chemotherapy elicits a survival beneﬁt.
Finally, Kayton et al. [6] describe data from 20 patients
collected over 30 years. These patients ranged in age from
6 to 25, with 35% of patients presenting with Intergroup
Rhabdomyosarcoma Study stage IV (metastatic) disease.
Patients with IRS Stage I (local) disease underwent surgery
alone,andnonehadevidenceoflocalrecurrenceatfollowup,
which ranged from 4 to 290 months; 20% of patients, how-
ever, developed detectable metastases at followup. For those
with IRS Stage IV disease, a variety of approaches including
radiation therapy to the primary tumor or metastases,chem-
otherapy, and excision of the primary mass ± metastasec-
tomy were attempted. The authors note no partial or com-
plete responses to a wide variety of chemotherapy regimens
attempted, including antimetabolites, alkylating agents, mi-
totic inhibitors, anthracyclines, or biologic agents. Similarly,
small numbers precluded clear conclusions regarding radi-
ation therapy. The aggregate 5-year survival for all patients
with ASPS was 83%, with 5-year progression-free survival6 Sarcoma
of 22%; of note, those presenting with a primary site tumor
>5cm in size all died before 5-year followup, whereas those
withtumorsize<5cmhada∼70%progression-freesurvival.
The data from this case series emphasize the importance
of complete microscopic resection with negative margins in
those with early stage disease, as well as the large bearing
tumor burden plays in determining survival. Furthermore,
for patients who present with metastases, the authors note
very short progression-free survival (median 12.5 months)
but much longer time of overall followup (median 36
months). This may reﬂect the indolent nature of the disease,
rather than the eﬀectiveness of surgical resection per se.
From these reports, there are no data to support the use
of any modality of therapy aside from surgery for ASPS;
no signiﬁcant survival advantages have been achieved by
utilizing chemotherapy or radiation for patients who have
local or metastatic disease at the time of diagnosis as com-
pared to patients who are not treated. The authors of these
studies, however, note the importance of palliation, when
necessary, and that though there are no data demonstrating
survival beneﬁt, radiation therapy should be considered in
speciﬁc cases where there is a large primary tumor burden.
Our recommendations based on these data are expectant
observation when metastatic disease is low volume and
nonprogressive on serial imaging.
6.TargetedTherapies andClinicalTrials
The resistance of ASPS tumors to conventional chemother-
apies and radiation makes this type of tumor challenging
to treat; however, a number of exciting clinical trials are
underway which are investigating novel targeted therapies.
These newer agents oﬀer many advantages over traditional
chemotherapeutic agents and radiotherapy, such as reduced
toxicity and daily outpatient use. The theoretical ability
to indeﬁnitely continue minimally toxic therapy becomes
especially important, given the indolent nature of ASPS even
in the context of metastatic disease. A number of trials
underway currently seek to focus on the overactivity of the
METreceptortyrosinekinasegeneinducedbytheASPSCR1-
TFE3 fusion protein. In addition, the vascular nature of
this tumor also suggests a potential role for antiangiogenic
agents.
One such trial focused on ARQ-197 (ArQule), a selective
inhibitorofthec-Metreceptortyrosinekinase.Thisdrugwas
tested in a Phase II study (NCI Clinical Trial NCT00557609)
examining the drug’s eﬀect on Microphthalmia Transcrip-
tion Factor Family (MiT) tumors, which include ASPS, clear
cell carcinoma, and renal cell carcinomas bearing a TFE3
translocation [41]. Preliminary data presented at the 2009
American Society of Clinical Oncology indicated that 15
of 17 patients treated with ARQ-197 demonstrated stable
disease at ∼29 weeks of therapy, with a disease control rate of
∼80% [42]. This drug has an excellent safety trial following
the completion of three Phase I trials, and although data are
not mature, they appear promising.
Along these same lines, multitargeted tyrosine kinase
inhibitors have also been investigated in small trials; suni-
tinib malate (SU11248, Sutent, Pﬁzer), a multitargeted RTK
inhibitor with antiangiogenic properties approved for treat-
ment of GIST and renal cancer, was recently trialed in 8
patients [43]. Five patients showed partial response, one had
stable disease and one progressed. Similarly, a phase II trial
with sorafenib (Nexavar, Bayer, NCI Trial NCT00330421),
another multitargeted tyrosine kinase inhibitor, showed that
in 28 patients, 12 had partial response and 6 had stable
disease, for a disease control rate of 78% [44]. Other clinical
trials underway for the treatment of ASPS include the Akt
inhibitor, KRX-0401 (Perifosine, Keryx/AOI, NCI Clinical
Trial NCT00401388), and antiangiogenic approaches such as
bevacizumab (Avastin, Genentech) or Cediranib (Recentin,
AstraZeneca) [45–47]. Preliminary data from two phase
II trials using Cediranib (Study code 2171IL0038) also
presented at the 2009 American Society of Clinical Oncology
showed that four of seven patients had a partial response,
two patients had a conﬁrmed reduction in tumor size, and
onepatientdemonstratedstabledisease[48].Furtherclinical
trials for Cediranib are currently open to accrual (NCI
Clinical Trials NCT01337401 and NCT00942877) [49, 50].
7. FutureDirections
The discovery of further novel therapeutic targets has been
aided by a number of recent reports providing broad and
targeted gene expression and immunohistochemical arrays.
Together, Stockwin et al. and Lazar et al. provide compre-
hensive studies characterizing gene expression proﬁles of
ASPS, with a focus on a number of key players involved in
angiogenesis, cell proliferation, and metastasis [51, 52]. For
instance, these manuscripts both identiﬁed upregulation of
MDK (midkine or neurite growth-promoting factor-2) and
Jag-1 (Jagged-1), which are regulators of angiogenesis. MDK
is a low molecular weight growth factor which antagonizes
VEGF signaling and that appears to be upregulated in
multiple solid tumors; Jag-1, in contrast, is the ligand for
the Notch-1 receptor and is a potent proangiogenic signal
[53–56]. There are numerous suggestions that both these
molecules represent excellent targets for novel therapeutics,
and there are preclinical data that are promising [57–59].
Stockwin et al. also demonstrated the expression of GPNMB,
a transmembrane protein which bears homology to the
melanoma antigen pMEL17. CDX-011, or Glembatumumab
(Celldex), is an antibody targeted against GPNMB (Trans-
membrane Protein NMB); this antibody was conjugated
to vedotin (monomethyl auristatin E), a highly potent
antimitotic agent, in recent Phase 2 trials for advanced
breast cancer and late-stage melanoma [60, 61]. These data
provide a rational basis for use of this drug in ASPS.
Finally, Martignoni et al. demonstrate that all tested samples
of alveolar soft part sarcomas diﬀusely express cathepsin
K, whose expression is driven by MITF in osteoclasts;
interestingly, renal cell carcinomas with the same ASPSCR1-
TFE3 translocation do not detectably express this protease
[62]. Argani et al. also reported the expression of cathepsin
Ki nP E C o m a s[ 32]. Odanacatib (MK-0822, Merck) is a
monoclonal antibody against cathepsin K and has been
studied in women with breast cancer with bony metastases;Sarcoma 7
again, cathepsin K may represent a potential therapeutic tar-
get [63].
8. Conclusions
In summary, alveolar soft part sarcomas are rare, unique
malignancies which grow indolently and remain diﬃcult
to treat despite decades of clinical experience. Recent data
have linked the speciﬁc t(X;17)(p11;25) translocation found
in all ASPS tumors studied to the overexpression of the
promitotic MET receptor tyrosine kinase, providing a model
for tumorigenesis. At this point, surgical methods are the
most eﬃcacious means of disease treatment; there are no
convincing data in support of conventional chemotherapy
or radiation therapy. New molecular therapies targeted to
tyrosine receptor kinases and antiangiogenic agents have
yielded promising data thus far, and these next-generation
therapies may soon comprise ﬁrst-line treatment for this
tumor type.
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